This paper examines how the Clinical Laboratory Improvement Amendments (CLIA) of 1988 govern urinalysis testing performed in physicians' offices. It outlines the distinction between waived, moderate-complexity, and high-complexity tests, explaining why waived urinalysis tests — including those for illicit drugs, pregnancy, kidney and liver function, and blood abnormalities — are increasingly popular in clinical settings. The paper also describes the Certificate of Waiver application process, regulatory requirements for waived testing, and the additional Provider-Performed Microscopy (PPM) certification that allows microscopic urine sediment examinations. Together, these frameworks enable convenient, low-oversight laboratory testing directly in provider offices.
The paper demonstrates effective regulatory synthesis — translating dense government policy language into accessible, organized prose without sacrificing accuracy. By grouping requirements under distinct certificate types (Waiver vs. PPM), the author makes compliance requirements easy to compare and apply, a technique especially valuable in health administration and medical writing.
The paper opens with a brief orienting introduction, then moves into two parallel regulatory sections — one on waived tests and one on PPM procedures — each covering the scope of tests permitted, the certification process, and oversight obligations. A short conclusion synthesizes the practical takeaway. This parallel structure mirrors the actual tiered framework of CLIA regulations, reinforcing the content through form.
All clinical laboratory services offered in the United States are regulated under the Clinical Laboratory Improvement Amendments (CLIA) of 1988 (Centers for Disease Control and Prevention [CDC], 2005, p. 2). The Centers for Medicare & Medicaid Services (CMS) administers the CLIA program, and CMS, CDC, and FDA are jointly responsible for implementing CLIA regulations.
CLIA regulations cover all laboratory tests conducted for medical purposes. Many of these tests no longer require intensive oversight procedures because manufacturers have designed them to be nearly foolproof and safe to use. Waived urinalysis tests include those detecting illicit drug use, pregnancy, liver and kidney problems, and blood abnormalities. The ease and speed with which these tests can be performed, combined with the relatively relaxed CLIA regulations governing their use, are making them increasingly popular in provider offices.
CLIA regulations draw distinctions between high-complexity, moderate-complexity, and low-complexity tests, based on how error-prone a given test might be and the associated safety concerns (CDC, 2005, p. 2). Low-complexity tests are typically "waived" from CLIA oversight and personnel training requirements, which are required for moderate- and high-complexity tests. Waived tests are becoming more common and more error-free; some can even be purchased over the counter in pharmacies for home use — pregnancy tests being a familiar example. For this reason, offering waived testing procedures in physician offices is becoming more popular because of the convenience and speed with which test results can be obtained. All that is needed to begin is to obtain a Certificate of Waiver from CMS and pay the $150 biannual fee.
CLIA waived urinalysis tests are available for a large number of applications and include testing for illicit drug use, kidney and liver function, pregnancy, and blood disorders (U.S. Food & Drug Administration, 2011). The most common format for these tests is test strips, which change to a specific color when exposed to a urine sample. The strips can then be graded by hand or by inserting them into small automated strip readers. In terms of safety, the standard biohazard precautions already in place in a typical physician's office are sufficient.
CLIA requires that the number of tests used be recorded and submitted on the CLIA application for waived testing, Form CMS-116 (Centers for Medicare & Medicaid Services [CMS], 2004). Tests used for quality control or proficiency testing should not be included in the count — only those ordered and used for patient specimens. Dipsticks or strips are counted as one test, regardless of how many different reagent pads may be included on the stick or strip. CLIA regulations require laboratories operating under a Certificate of Waiver to follow the manufacturer's instructions when performing each test.
Laboratories that conduct non-waived tests must engage in rigorous and ongoing self-assessment of performance. This includes proficiency testing of personnel, investigation of complaints, documentation of all methods, procedures, training, equipment calibration and maintenance, and remedial actions taken. Laboratories operating under a Certificate of Waiver are not required to perform the same oversight functions. However, should the Regional CLIA Office receive a complaint, suspect the laboratory is performing non-waived tests, or have concerns about the safety or reliability of a waived test, a survey may be conducted.
Physicians can now perform a number of urinalysis tests in their own offices with limited oversight requirements under a Certificate of Waiver. Adding a Certificate of PPM Procedures would further expand the range of laboratory tests that can be performed without increasing the regulatory oversight burden.
You’re 73% through this paper. Sign up to read the remaining 1 section.
Sign Up Now — Instant Access Already a member? Log inAlways verify citation format against your institution’s current style guide requirements.